Senate Pandemic Bill Advances Without Provision Expediting FDA Reviews Based On Foreign Data
Senate committee approves legislation aimed at strengthening the US public health and medical preparedness and response system. Bill includes several provisions impacting FDA but not its 'gold standard' approval process.
You may also be interested in...
The year-end package of US FDA reforms reflects the impact of one now-retired US Senator: North Carolina’s Richard Burr’s objections helped take out a number of ‘anti-innovation’ provisions – while still securing inclusion of a ‘Platform Technologies’ pathway that might otherwise not have been enacted.
The draft bipartisan user fee reauthorization bill includes more than 40 ride-along provisions to make changes at the US FDA. But there are at least three other bills moving in Congress that also make FDA reforms.
President Biden’s budget request would add $1.63bn in mandatory funding to the FDA budget in FY 2023.